ArticleInfection and immunity1998
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family.
Article in Infection and immunity, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.
- Potential antigenic targets used in immunological tests for diagnosis of tegumentary leishmaniasis: A systematic review.PloS one · 2021Pooled it
- Trial
- An Overview of the Factors Related toVaccines · 2026Review
- Leishmania pyruvate kinase and mitochondrial processing protease: Two novel vaccine candidates, selected via a seroproteomic approach, trigger a protective immune response against murine cutaneous leishmaniasis.Medical microbiology and immunology · 2025Article
- Inflammatory CD11bPathogens (Basel, Switzerland) · 2024Article
- Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate inFrontiers in immunology · 2023Article
- Evaluation of a Novel Multi-Epitope Peptide Vaccine Candidate from LACK, LeIF, GP63, SMT Antigens ofArchives of Razi Institute · 2022Article
- Vaccination in Leishmaniasis: A Review Article.Iranian biomedical journal · 2022Article
- Anti-mitochondrial Tryparedoxin Peroxidase Monoclonal Antibody-Based Immunohistochemistry for Diagnosis of Cutaneous Leishmaniasis.Frontiers in microbiology · 2021Article
- Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.Human vaccines & immunotherapeutics · 2020Review
- Cloning and molecular characterization of thiol-specific antioxidant gene of Leishmania tropica Turkey isolateTurkish journal of medical sciences · 2019Article
- Emerging therapeutic targets for treatment of leishmaniasis.Expert opinion on therapeutic targets · 2018Review
- Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and In Silico Studies.International journal of molecular sciences · 2017Article
- Efficacy of a new rapid diagnostic test kit to diagnose Sri Lankan cutaneous leishmaniasis caused by Leishmania donovani.PloS one · 2017Article
- The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2016Article
- Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2016Article
- Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.PLoS neglected tropical diseases · 2016Article
- Post-Genomics and Vaccine Improvement for Leishmania.Frontiers in microbiology · 2016Review
- Efficacy of Recombinant Canine Distemper Virus Expressing Leishmania Antigen against Leishmania Challenge in Dogs.PLoS neglected tropical diseases · 2015Article
- DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant.PLoS neglected tropical diseases · 2014Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Vaccination of BALB/c mice with Leishmania major promastigote culture filtrate proteins plus Corynebacterium parvum confers resistance to infection with L. major. To define immunogenic components of this protein mixture, we used sera from vaccinated mice to screen an L. major amastigote cDNA expression library. One of the immunoreactive clones thus obtained encoded a novel protein of L. major with a molecular mass of 22.1 kDa. The predicted amino acid sequence of this clone exhibited significant homology to eukaryotic thiol-specific-antioxidant (TSA) proteins. Therefore, we have designated this protein L. major TSA protein. Southern blot hybridization analyses indicate that there are multiple copies of the TSA gene in all species of Leishmania analyzed. Northern blot analyses demonstrated that the TSA gene is constitutively expressed in L. major promastigotes and amastigotes. Recombinant TSA protein containing an amino-terminal six-histidine tag was expressed in Escherichia coli with the pET17b system and was purified to homogeneity by affinity chromatography. Immunization of BALB/c mice with recombinant TSA protein resulted in the development of strong cellular immune responses and conferred protective immune responses against infection with L. major when the protein was combined with interleukin 12. In addition, recombinant TSA protein elicited in vitro proliferative responses from peripheral blood mononuclear cells of human leishmaniasis patients and significant TSA protein-specific antibody titers were detected in sera of both cutaneous-leishmaniasis and visceral-leishmaniasis patients. Together, these data suggest that the TSA protein may be useful as a component of a subunit vaccine against leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.